Navigation Links
Celtic Pharma Announces Issuance of U.S. Patent 7,816,323 for Xerecept® in Combination with Avastin® as a Treatment for Breast and Colon Cancers
Date:10/21/2010

NEW YORK, LONDON and BERMUDA, Oct. 21 /PRNewswire/ -- Celtic Pharmaceutical Holdings L.P. ("Celtic Pharma") today announced that the U.S. Patent Office has issued U.S. patent 7,816,323, for novel methods to treat breast and colon cancers using a combination therapy of Xerecept® with Avastin®.  The patent is based on in vivo data demonstrating the successful inhibition of tumor growth using a combination therapy approach. This patent was filed in April 2010, recognized as "special" based on specific criteria of the Patent and Trademark Office, and therefore expedited and issued on October 19, 2010.

Xerecept is a synthetic version of the natural peptide hormone Corticotrophin Releasing Factor. Celtic Pharma has been pursuing Xerecept's clinical development as a treatment for edema associated with cerebral tumors.  In trials to date, Xerecept has demonstrated that its use enables significant reductions or elimination of corticosteroid dosing in cerebral tumor patients, and that patients tolerate chronic daily Xerecept dosing over several years without significant side effect issues.

Celtic Pharma and its co-investigators first presented the results from Xerecept administered in combination with Avastin against both breast and colon cancers at the Annual Meeting of the American Association of Cancer Research (AACR) in April, 2010.  The data showed both synergistic activity between the two molecules and potentiation of Avastin by Xerecept.

"Celtic Pharma believes that Xerecept continues to show great promise as an important addition to the therapeutic options in clinical oncology," said Stephen Evans-Freke and John Mayo, Managing General Partners of Celtic Pharma.  "We are committed to ensuring the potential of Xerecept is realized, both in its application for the treatment of cerebral edema and in this exciting new opportunity as a potential oncology drug in major solid tumor types."

Dr. Jerry Posner, F
'/>"/>

SOURCE Celtic Pharmaceutical Holdings L.P.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Celtic Pharma Provides Update on XERECEPT(R) Clinical Program
2. Celtic Pharma Announces Update on Status of XERECEPT(R) Program Sale Planned in 2009
3. Neurobiological Technologies Partner, Celtic Pharma, Announces Results of XERECEPT(R) Phase 3 Clinical Program
4. Celtic Pharma Announces Initiation of Pediatric Dose Tolerance Trial Evaluating XERECEPT(R) in Pediatric Patients with Primary and Metastatic Brain Tumors
5. Celtic Pharma Announces Initiation of Phase III Trial of TDT 067 for the Treatment of Onychomycosis
6. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
7. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
8. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
9. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
10. Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management
11. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... August 3, 2015 Shire ... today that it has acquired New ... for $300 million. With the acquisition, Shire acquires ... combining 0.6% povidone iodine (PVP-I) and 0.1% dexamethasone), ... of infectious conjunctivitis, an ocular surface condition commonly ...
(Date:8/2/2015)... , Aug. 3, 2015  Lexicon Pharmaceuticals, ... the pivotal TELESTAR Phase 3 clinical trial met ... telotristat etiprate in treating cancer patients with carcinoid ... current standard of care. Telotristat etiprate was discovered ... technology, and is the company,s first discovery to ...
(Date:7/31/2015)... -- More than 1,500 substance abuse prevention and treatment ... Indianapolis Aug. 2-6 for Community Anti-Drug ... . The week-long training, held at the JW Marriott, ... nation,s biggest public health challenges – youth drug use. ... one-of-a-kind intensive training opportunity, offering more than 70 half-day ...
Breaking Medicine Technology:Shire Acquires Privately Held Foresight Biotherapeutics Inc., Boosting Ophthalmics Portfolio with Late-Stage Asset 2Shire Acquires Privately Held Foresight Biotherapeutics Inc., Boosting Ophthalmics Portfolio with Late-Stage Asset 3Shire Acquires Privately Held Foresight Biotherapeutics Inc., Boosting Ophthalmics Portfolio with Late-Stage Asset 4Shire Acquires Privately Held Foresight Biotherapeutics Inc., Boosting Ophthalmics Portfolio with Late-Stage Asset 5Shire Acquires Privately Held Foresight Biotherapeutics Inc., Boosting Ophthalmics Portfolio with Late-Stage Asset 6Lexicon Pharmaceuticals Reports Positive Top-Line Results For Pivotal Phase 3 Telotristat Etiprate Study In Cancer Patients With Carcinoid Syndrome 2Lexicon Pharmaceuticals Reports Positive Top-Line Results For Pivotal Phase 3 Telotristat Etiprate Study In Cancer Patients With Carcinoid Syndrome 3Lexicon Pharmaceuticals Reports Positive Top-Line Results For Pivotal Phase 3 Telotristat Etiprate Study In Cancer Patients With Carcinoid Syndrome 4Lexicon Pharmaceuticals Reports Positive Top-Line Results For Pivotal Phase 3 Telotristat Etiprate Study In Cancer Patients With Carcinoid Syndrome 5Lexicon Pharmaceuticals Reports Positive Top-Line Results For Pivotal Phase 3 Telotristat Etiprate Study In Cancer Patients With Carcinoid Syndrome 6Community Leaders From Across The Country Head To Indianapolis For CADCA 2015 Mid-Year Training Institute Aug. 2-6 2
... Medical AB ( http://www.omxgroup.com, OMX: DIAM B; ... http://www.otcqx.com, OTC: ... B)(OTC: DMYDY)announced today that the Swedish Medical Products,Agency (MPA) has ... therapeutic diabetes vaccine Diamyd(R)., (Logo: http://www.newscom.com/cgi-bin/prnh/20080314/297194 ), ...
... Onset with SYMBICORT with Improved Lung Function within ... ... WILMINGTON, Del., March 18 Data from a new,study demonstrated ... greater,and faster bronchodilatory effects, or opening of the airways, compared,with ...
Cached Medicine Technology:Diamyd(R) Diabetes Vaccine Receives Approval to Start Phase III Trials in Europe 2Study Compares Bronchodilatory Effects of SYMBICORT(R) and Advair in Adults With Asthma 2Study Compares Bronchodilatory Effects of SYMBICORT(R) and Advair in Adults With Asthma 3Study Compares Bronchodilatory Effects of SYMBICORT(R) and Advair in Adults With Asthma 4
(Date:8/3/2015)... Pass, OR (PRWEB) , ... August 03, 2015 ... ... Northeast California’s Modoc National Forest, to Ahjumawi Lava Springs, California’s northernmost and among ... of California’s largest untapped ground water aquifers, whose main outflow is at Ahjumawi ...
(Date:8/3/2015)... ... August 03, 2015 , ... From 2006-2017 the number ... according to market research compiled for the National Association of Dental Laboratories ( ... Labor, Bureau of Labor Statistics. As the number of dental laboratories decreases, dentists ...
(Date:8/3/2015)... ... 2015 , ... Constantin Vasilica, 48 from Romania wanted to have an alternative ... many years of suffering and using medications with strong side effects. This had already ... extra time off or wait longer hours in the waiting rooms. Instead, he went ...
(Date:8/3/2015)... ... 03, 2015 , ... The American Institute of Architects ... to collaborate across a wide range of initiatives ranging from code development and ... , “Our combined membership, consisting of practicing design professionals, code officials, and the ...
(Date:8/2/2015)... ... August 03, 2015 , ... A new Phase I research study is ... study is led by Kenneth G. Lucas, M.D. , chief of the division ... with colleagues at Kosair Children’s Hospital and in the UofL Department ...
Breaking Medicine News(10 mins):Health News:Medicine Lake Aquifer could ease California drought says fresh water advocate Sharon Kleyne – but is this necessary? 2Health News:Medicine Lake Aquifer could ease California drought says fresh water advocate Sharon Kleyne – but is this necessary? 3Health News:Medicine Lake Aquifer could ease California drought says fresh water advocate Sharon Kleyne – but is this necessary? 4Health News:Dental Association Announces Impending Reduction of Dental Laboratories Could Impact Dentists 2Health News:Dental Association Announces Impending Reduction of Dental Laboratories Could Impact Dentists 3Health News:Chinese Health Care Provider Heshoutang Now Give Patients Complimentary Online Healing Options 2Health News:Chinese Health Care Provider Heshoutang Now Give Patients Complimentary Online Healing Options 3Health News:Architects, International Code Council Ink Five-Year Collaborative Agreement 2Health News:Architects, International Code Council Ink Five-Year Collaborative Agreement 3Health News:UofL Physicians Conducting Vaccine Trial for Children with Relapsed Tumors at Kosair Children’s Hospital 2
... Exposition Park LOS ANGELES, ... March of Dimes premier fundraising event that benefits all babies--those ... thrive. 11,000 walkers are expected at this largest March for ... Exposition Park, at the corner of S. Figueroa and 39th ...
... associations representing the state,s 114 hospitals have reached a ... 2010.Among other principles, the groups urged the state to ... agreed on a minimum floor that all hospitals should ... shared today with members of the state Legislature by ...
... Saturday, April 25 from 9 a.m. until noon, ... (NAMI-OC) will bring together speakers, agencies and service ... Front Line conferences provide important information on PTSD ... and suicide prevention. The conference is designed not ...
... The National Medical Association (NMA), the nation,s premier ... funding in the amount of $120,000 from the ... of a three-year grant commitment, designed "to promote ... sustaining collaboration among partner organizations."Partner organizations for this ...
... favors people in urban areas , , TUESDAY, April 21 (HealthDay ... or remote areas are not less likely to get a ... finds. , Researchers analyzed U.S. data on 699,751 adults ... list between 1995 and 2007. After about two years on ...
... Patients who drank before diagnosis had reduced risk of ... (HealthDay News) -- Patients with non-Hodgkin lymphoma who drank ... risk of relapse or death, according to a study ... researchers looked at more than 500 women with non-Hodgkin ...
Cached Medicine News:Health News:Farmers Insurance Joins March of Dimes March for Babies April 25, 2009 2Health News:Hospital Groups Stand United on State Budget 2Health News:Hospital Groups Stand United on State Budget 3Health News:Hospital Groups Stand United on State Budget 4Health News:National Medical Association Receives Funding From Kellogg for Training Community Advocates 2Health News:Distance No Bar to Kidney Transplants in Remote Areas 2Health News:Wine May Guard Against Lymphoma Recurrence 2
A patient skin prepping solution in a self-contained applicator combining two proven broad-spectrum antimicrobials: alcohol for fast kill and fast drying (3 minutes on skin), and an iodophor for pers...
These are simple but effective single-dose, hands-off, ampulized applicators have revolutionized skin preparation in healthcare facilities....
Pre-Saturated Sponge Sticks...
... Sterile E*Kits® can be a valuable ... care; when the items necessary for a ... facility protocols and continuum of care are ... are packaged in sequence of use, allowing ...
Medicine Products: